A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.
Saved in:
| Title: | A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting. |
|---|---|
| Authors: | Jones S; Sarah Cannon Research Institute, Nashville, TN., Falchook G; Sarah Cannon Research Institute at HealthOne, Denver, CO., Graff S; HCA Midwest Kansas City, Kansas City, KS., Arrowsmith E; Tennessee Oncology, PLLC, Nashville, TN., Kilari D; Medical College of Wisconsin, Milwaukee, WI., Gersten TA; Florida Cancer Specialists and Research Institute East, Wellington, FL., Hussein M; Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute North, Tavares, FL., Percent I; Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute South, North Port, FL., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN.; SCRI Oncology Partners, Nashville, TN. |
| Source: | The oncologist [Oncologist] 2026 Jul 22. Date of Electronic Publication: 2026 Jul 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyag279 |
